Innovative Pharmaceutical Biotech Balance Sheet Health
Financial Health criteria checks 0/6
Innovative Pharmaceutical Biotech has a total shareholder equity of HK$319.4M and total debt of HK$1.1B, which brings its debt-to-equity ratio to 330%. Its total assets and total liabilities are HK$1.4B and HK$1.1B respectively.
Key information
330.0%
Debt to equity ratio
HK$1.05b
Debt
| Interest coverage ratio | n/a |
| Cash | HK$3.08m |
| Equity | HK$319.43m |
| Total liabilities | HK$1.06b |
| Total assets | HK$1.38b |
Recent financial health updates
Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?
Aug 12
Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?
Feb 18Recent updates
Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?
Aug 12Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)
Jan 05Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?
Feb 18Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.
Nov 26
Financial Position Analysis
Short Term Liabilities: 399's short term assets (HK$9.8M) do not cover its short term liabilities (HK$391.6M).
Long Term Liabilities: 399's short term assets (HK$9.8M) do not cover its long term liabilities (HK$672.0M).
Debt to Equity History and Analysis
Debt Level: 399's net debt to equity ratio (329.1%) is considered high.
Reducing Debt: 399's debt to equity ratio has increased from 95% to 330% over the past 5 years.
Debt Coverage: 399's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 399's interest payments on its debt are well covered by EBIT.